Exicure is actively pursuing partnership opportunities in the field of nucleic acid therapeutics. Our differentiating approach combines our automated and high-throughput nucleic acid synthesis and screening facilities with our expertise in identifying and developing highly potent oligonucleotide candidates and moving from the bench to the clinic quickly.
Our expertise in oligonucleotide development spans across several therapeutic areas including neuroscience, dermatology, and immuno-oncology. We are currently engaged in out-licensing activities with Exicure’s TLR9 agonist, cavrotolimod that demonstrates robust innate and adaptive immune response with P1b/2 clinical data. You can find the latest information here and can contact us for more information.